Provectus's Use of Social Media Channels
The Company's proposed use of certain social media accounts to communicate information and observations about Provectus and its business, and comply with its disclosure obligations under Regulation FD
Provectus issued an 8-K today (April 17, 2023 filing) noting that, while the Company uses and will continue to use press releases distributed by GlobeNewswire® (noted here on Provectus’s website), filings with the SEC (available here on EDGAR), and the Company’s website (www.provectusbio.com) to disclose material company financial, operational, and other information, Provectus also intends to use certain social media accounts to disclose information and observations about the Company and its business and to comply with Provectus’s disclosure obligations under Regulation FD.
These social media channels are:
Substack (provectus.substack.com),
Twitter (@ProvectusBio; twitter.com/provectusbio), and
LinkedIn (linkedin.com/company/provectus-biopharmaceuticals).
In the Company’s 8-K today, Provectus further noted that the information and observations posted by the Company through these social media channels may be deemed material. Accordingly, Provectus encouraged investors to monitor these social media channels in addition to following the Company’s press releases, SEC filings, and website. Provectus also noted that it will no longer use Provectus News, an emailed newsletter, after a final communication today about the Company’s use of social media channels.
Provectus Substack may be, in a manner of speaking, a re-creation of the single-company (i.e., single-topic) blog that one of the PRH stockholders started in 2011 (Dominic Rodrigues, now a member of Provectus’s leadership team). That is, the goal and aims of Provectus Substack would be to be a blog about all things Provectus, especially about all things small molecule halogenated xanthene (HX) medical science, lead molecule rose bengal sodium (RBS), and, thus, RBS drug discovery and clinical development. For historical context, a “group” of stockholders (i.e., PRH) entered into a Definitive Financing with the Company in 2017. PRH, then and now, specifically disclaims that it was or is a “group” as defined in U.S. federal securities laws.
“Provectus Blog 1.0,” a then-blog unaffiliated/not associated with Provectus (i.e., the writings, musings, perspectives, and commentaries about the Company’s medical science and the biotechnology business that it was to have underpinned that was authored by a PRH name who otherwise was a random shareholder prior to the 2017 Definitive Financing transaction), grew in readership from ∼60 unique visitors, ∼550 page views, and ∼300 visits per month starting in 4Q11 to ∼3,200 unique visitors, ∼28,000 page views, and ∼9,000 visits per month in 4Q16, which was the quarter that preceded the above mentioned 2017 Definitive Financing transaction. The five-year CAGRs of this readership increase were 105%, 120%, and 100%, respectively. Blog 1.0 readership peaked in 1Q14, along with the Company’s then-share price, attracting ∼4,200 unique visitors, ∼47,000 page views, and ∼20,000 visits per month.
We hope that Provectus Substack, or “Provectus Blog 2.0,” may be a venue for the Company to share information, observations, insights, and commentaries about, among other things, Provectus, its HX medical science, RBS drug discovery and clinical development, competitive landscape(s), etc., and the business of the biotechnology and pharmaceutical industries as they relate to Provectus’s place and activities in it.
An example of a forthcoming Provectus Substack post may be the medical science and clinical trial design rationales for potential future randomized controlled trials (RCTs) in cutaneous tumors and visceral hepatic tumors treated with the Company’s investigational small molecule cancer immunotherapy PV-10 in combination therapy settings, the clinical trial protocols for which Provectus has completed or is completing. For example, the post may discuss the specifics and generalities of:
Study patient population,
RCT primary, secondary, and exploratory endpoints: e.g., better leveraging PV-10’s effect size and pharmacokinetics,
Endpoint measurement: e.g., “living in a RECIST world,” PERCIST, different initial surrogate endpoints for overall survival than progession-free survival, etc., and
Immune correlative clinical companion work (i.e., to potentially establish [or refute] the “immunotherapy” in the phrase and description cancer immunotherapy PV-10).
We look forward to your readership and feedback.
Where to Find Available Information
Investors and others should note that Provectus Biopharmaceuticals, Inc. (the Company) uses, and will continue to use, press releases distributed by GlobeNewswire®, filings with the Securities and Exchange Commission (SEC), and the Company's website (provectusbio.com) to disclose material financial and operational information to the Company's shareholders, prospective investors, the media, and others interested in the Company. The Company also intends to use certain social media accounts as a means of disclosing information and observations about the Company and its business, and for complying with the Company's disclosure obligations under Regulation FD: the Provectus Substack account (provectus.substack.com), the @ProvectusBio Twitter account (twitter.com/provectusbio), and the Company's LinkedIn account (linkedin.com/company/provectus-biopharmaceuticals). The information and observations that the Company posts through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following the Company's press releases, SEC filings, and website. The social media channels that the Company intends to use as a means of disclosing the information described above may be updated from time to time.
Forward-Looking Statements
The information in Provectus’s Substack post may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in Provectus’s Substack are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of:
the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and
Provectus’ Quarterly Report on Form 10-Q for the period ended September 30, 2022.